Our investors share our vision and bring deep expertise and experience in developing promising companies such as Artios.

SV Health Investors

SV Health Investors (‘SV’) is a leading international life sciences venture capital firm. SV’s affiliated funds have been investing in life sciences companies since the early 1980s and the firm closed its first dedicated life sciences fund in 1994.

The SV team manages six private venture capital funds with approximately $2.1 billion of capital under management. The firm employs a diversified strategy within life sciences in order to selectively capitalise on an expanding opportunity in biotech, medical devices and healthcare services. SV has offices in Boston, London and San Francisco.


M Ventures

M Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From our headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by great entrepreneurs. M Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. M Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.


Arix Bioscience

Arix Bioscience plc is a global healthcare and life science company. Headquartered in London and with an office in New York, Arix Bioscience plc sources and develops businesses addressing medical innovation at all stages of development and is supported with access to breakthrough academic science

Our extensive experience in academic science, clinical and commercial strategy, company operations, venture capital, mergers and acquisitions and corporate finance puts us in an especially strong position build and support a wide range of businesses and technologies.

Arix Bioscience plc has exclusive or privileged agreements with leading universities in the UK, Europe and Australia providing direct access to innovative new technologies. We also have access to a broad range of research projects from US academic institutions.


Touchstone Innovations

Touchstone Innovations plc (formerly Imperial Innovations Group plc or just “Innovations”) creates, builds and invests in pioneering technology companies and licensing opportunities developed from outstanding scientific research from the ‘Golden Triangle’, the geographical region broadly bounded by London, Cambridge and Oxford.

Innovations supports scientists and entrepreneurs in the commercialisation of their ideas through protecting and licensing out intellectual property (through its Technology Transfer subsidiary, Imperial Innovations Limited), by leading the formation of new companies, by recruiting high calibre management teams and by providing investment and encouraging co-investment. Innovations remains an active investor over the life of its portfolio companies, with the majority of Innovations’ investment going into businesses in which it is already a shareholder.

Between Innovations’ admission to AIM (August 2006) and 31 January 2017, Innovations has invested a total of £335.7 million across its portfolio companies, which have collectively raised investment of £1.5 billion.



AbbVie Ventures

AbbVie Ventures is the corporate strategic venture capital arm of Abbvie and a core component of AbbVie’s integrated approach to external innovation.  AbbVie Ventures invests globally in early stage transformational life sciences companies that augment our core R&D areas within oncology, autoimmune/inflammatory diseases, neurodegenerative diseases, and hepatology. We build strong relationships with fellow investors, entrepreneurs and industry experts that provide us insights into novel technologies and biology as well as early exposure to potential business development opportunities. Our expertise in drug discovery, development, and commercialization serves as a valuable resource to our portfolio companies. Our team is located at AbbVie headquarters in North Chicago, Boston/Cambridge, and the San Francisco Bay area.


Sixth Element Capital

Sixth Element Capital is an independent venture capital company that manages the CRT Pioneer Fund.

The CRT Pioneer Fund has been established with Cancer Research Technology (CRT) and the European Investment Fund (EIF) to create a £50M investment fund to bridge the investment gap between cancer drug discovery and early development. It will take potential cancer drugs, primarily discovered by Cancer Research UK, from discovery through to entry to Phase II clinical trials before partnering with pharmaceutical and biotechnology companies.